Entero Therapeutics, Inc. 8-K Filing
Ticker: GRDX · Form: 8-K · Filed: Oct 31, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $3,876,738, $2.5 m, $35 million, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Entero Therapeutics, Inc. (ticker: GRDX) to the SEC on Oct 31, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ch registered Common Stock, par value $0.0001 per share ENTO The Nasdaq Stock Mar); $3,876,738 (the Company's stockholders' equity of ($3,876,738) as reported in the Company's Annual Re); $2.5 m (2024 was below the required minimum of $2.5 million, and because, as of April 10, 202); $35 million (he market value of listed securities of $35 million or net income from continuing operation); $500,000 (et income from continuing operations of $500,000 in the most recently completed fiscal y).
How long is this filing?
Entero Therapeutics, Inc.'s 8-K filing is 3 pages with approximately 759 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 759 words · 3 min read · ~3 pages · Grade level 14.8 · Accepted 2025-10-31 16:00:31
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO The Nasdaq Stock Mar
- $3,876,738 — the Company's stockholders' equity of ($3,876,738) as reported in the Company's Annual Re
- $2.5 m — 2024 was below the required minimum of $2.5 million, and because, as of April 10, 202
- $35 million — he market value of listed securities of $35 million or net income from continuing operation
- $500,000 — et income from continuing operations of $500,000 in the most recently completed fiscal y
- $2.5 million — it had stockholders' equity of at least $2.5 million in compliance with the Equity Rule as a
Filing Documents
- tm2529898d1_8k.htm (8-K) — 27KB
- 0001104659-25-104917.txt ( ) — 188KB
- fwbi-20251028.xsd (EX-101.SCH) — 3KB
- fwbi-20251028_lab.xml (EX-101.LAB) — 33KB
- fwbi-20251028_pre.xml (EX-101.PRE) — 22KB
- tm2529898d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events As previously disclosed in Form 8-K filed on April 14, 2025 by Entero Therapeutics, Inc. (the "Company"), on April 11, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) (the "Equity Rule"), because the Company's stockholders' equity of ($3,876,738) as reported in the Company's Annual Report on Form 10-K for the period ended December 31, 2024 was below the required minimum of $2.5 million, and because, as of April 10, 2025 the Company did not meet the alternative compliance standards, relating to the market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. As previously disclosed in Form 8-K filed on June 30, 2025 by the Company, based on the timely submission by the Company of a compliance plan, the Company received a letter on June 25, 2025 from Nasdaq granting an extension to the Company until October 8, 2025 to regain compliance with the Equity Rule, subject to the Company complying with certain terms of the extension. In the Form 8-K filed by the Company on October 6, 2025, the Company disclosed that that it believed that it had stockholders' equity of at least $2.5 million in compliance with the Equity Rule as a result of the share exchange agreement dated September 30, 2025, between the Company, GridAI Corp, a Nevada corporation ("GridAI"), and the stockholders of all of the issued and outstanding shares of GridAI (the "Share Exchange"). On October 8, 2025, the Company also submitted a letter to Nasdaq stating that the Company was compliant with the Equity Rule as a result of the Share Exchange. On October 28, 2025, the Company rece
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. October 31, 2025 By: /s/ Jason D. Sawyer Name: Jason D. Sawyer Title: Interim Chief Executive Officer